NewAmsterdam Pharma Company NV Overview
Latest ROE for NewAmsterdam Pharma Company NV: -41.1% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-41.10%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NAMS is -41.1%. That is below the sector sector average of -5.93%. Investors often review this figure alongside NewAmsterdam Pharma Company NV's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, NAMS currently prints -41.1% for ROE, while the sector average sits near -5.93%. That is roughly 592.8% below the sector mean. Large gaps often invite a closer look at NewAmsterdam Pharma Company NV's growth, margins, and balance sheet.
Return on Equity shows how effectively NewAmsterdam Pharma Company NV converts resources into returns. At -41.1%, NAMS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NAMS's ROE (-41.1%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
